Cyclooxygenase-1
(COX-1) and its isozyme COX-2 are key enzymes
in the syntheses of prostanoids. Imaging of COX-1 and COX-2 selective
radioligands with positron emission tomography (PET) may clarify how
these enzymes are involved in inflammatory conditions and assist in
the discovery of improved anti-inflammatory drugs. We have previously
labeled the selective high-affinity COX-1 ligand, 1,5-bis(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-1,2,4-triazole (PS13), with carbon-11 (t
1/2 = 20.4 min). This radioligand ([11C]PS13)
has been successful for PET imaging of COX-1 in monkey and human brain
and in periphery. [11C]PS13 is being used in clinical investigations.
Alternative labeling of PS13 with fluorine-18 (t
1/2 = 109.8 min) is desirable to provide a longer-lived radioligand
in high activity that might be readily distributed among imaging centers.
However, labeling of PS13 in its 1,1,1-trifluoroethoxy group is a
radiochemical challenge. Here we assess two labeling approaches based
on nucleophilic addition of cyclotron-produced [18F]fluoride
ion to gem-difluorovinyl precursors, either to label
PS13 in one step or to produce [18F]2,2,2-trifluoroethyl p-toluenesulfonate for labeling a hydroxyl precursor. From
the latter two-step approach, we obtained [18F]PS13 ready
for intravenous injection in a decay-corrected radiochemical yield
of 7.9% and with a molar activity of up to 7.9 GBq/μmol. PET
imaging of monkey brain with [18F]PS13 shows that this
radioligand can specifically image and quantify COX-1 without radiodefluorination
but with some radioactivity uptake in skull, ascribed to red bone
marrow. The development of a new procedure for labeling PS13 with
fluorine-18 at a higher molar activity is, however, desirable to suppress
occupancy of COX-1 by carrier at baseline.